Groundbreaking Discovery Of CD99L2 Gene Variants Solves Genetic Mystery Of X Linked Spastic Ataxia

Researchers solve a genetic puzzle by identifying CD99L2 gene variants as the driver of X-linked spastic ataxia and synaptic disruption.

By: AXL Media

Published: Mar 17, 2026, 12:07 PM EDT

Source: Information for this report was sourced from Ruhr University Bochum

Decoding the Genetic Architecture of Rare Movement Disorders

The quest to identify the molecular origins of rare neurodegenerative conditions has reached a significant milestone with the discovery of a new disease-causing gene. Despite the prevalence of high-throughput sequencing in modern medicine, the exact genetic triggers for many movement disorders have remained elusive for decades. A research coalition from Ruhr University Bochum and the University of Tübingen recently solved a critical piece of this puzzle by examining 2,811 patients suffering from ataxia, dystonia, and hereditary spastic paraplegia. Their findings, published in Nature Communications, pinpoint variants of the CD99L2 gene as the definitive cause of X-linked spastic ataxia, a condition characterized by a debilitating combination of movement discoordination and spastic paralysis.

Uncovering a Hidden Neurological Role for Immune Related Genes

Prior to this study, the CD99L2 gene was almost exclusively associated with immune system functions, with no documented role in the human nervous system. The research team, led by Dr. Tobias Haack and Dr. Jonasz Weber, utilized genome-wide analysis coupled with cellular biological experiments to prove that this gene is actually a vital component of neuronal signaling. This shift in understanding demonstrates that genes previously categorized within one biological system may hold untapped significance in others. By bridging the gap between immune research and neurology, the scientists were able to map the previously unknown pathway that leads from a genetic mutation to the onset of physical ataxia symptoms.

The Molecular Mechanics of Synaptic Disruption

At the cellular level, the protein encoded by CD99L2 acts as a necessary activating partner for a calcium-dependent protease known as CAPN1. This protease was already a recognized factor in spastic paraplegia, but the mechanism of its activation was poorly understood until now. Dr. Weber’s team demonstrated that disease-causing variants lead to a failure in the production of the CD99L2 protein, which in turn prevents it from interacting with CAPN1. This failure triggers a cascade of dysregulation in neuronal signal pathways and specifically disrupts synaptic processes, providing a plausible biological explanation for why patients experience a loss of motor control and cerebellar involvement.